News

Presidio Property Trust Declares Dividend on Series D Stock

Presidio Property Trust Declares Dividend on Series D Stock

Presidio Property Trust Announces Cash Dividends

In a significant announcement, Presidio Property Trust, Inc. has declared a cash dividend on its Series D Cumulative Redeemable Perpetual Preferred Stock. This declaration comes from the Company’s Board of Directors, highlighting its commitment to delivering value to its shareholders.

Details of the Dividend Announcement

Presidio has confirmed that the dividend will be distributed for the months ahead, covering January through March. Shareholders can expect a consistent payout of $0.19531 per share, payable in cash. The record date for the January dividend will be January 31, followed by similar dates for the subsequent months.

Understanding the Series D Preferred Stock

The Series D Preferred Stock represents a vital component of Presidio's financing structure. As an investor, understanding the terms of this stock is crucial. Preferred stocks often provide dividends, and in this case, the preferred stockholders will benefit from the declared amounts over the next few months.

Implications for Investors

The consistent dividend payments reflect Presidio’s strategic focus on generating stable returns, which can enhance a portfolio's income aspect. Investors interested in real estate investment trusts (REITs) often look for such signals of financial health and operational success.

About Presidio Property Trust

Presidio is a robust real estate investment trust that primarily focuses on model home properties leased to homebuilders. Their asset portfolio also includes varied commercial properties like office, industrial, and retail spaces, strategically located to maximize rental income.

Broad Portfolio of Properties

With properties centered mainly in regions like Colorado, as well as in Maryland and Texas, Presidio's holdings are diversified. This geographical spread helps dilute risks associated with real estate markets and strengthens their market position.

Investing in Innovation

Additionally, Presidio has a stake in Conduit Pharmaceuticals Inc. This investment aligns with their growth strategy, showcasing their involvement not just in real estate but also in the life sciences sector. Such investments indicate their vision for diversified revenue streams.

Investor Relations Contact Information

For any inquiries regarding investments or shareholder information, please reach out to Presidio's Investor Relations:

Lowell Hartkorn
Investor Relations, Presidio Property Trust, Inc.
Telephone: (760) 471-8536 x1244
Email: LHartkorn@presidiopt.com

Frequently Asked Questions

What is the declared dividend for Series D Preferred Stock?

The declared dividend is $0.19531 per share for the months of January, February, and March.

When will the dividends be paid?

Dividends are scheduled for payment on February 17, March 17, and April 15 for their respective months.

How does the Series D Preferred Stock benefit investors?

Investors benefit through regular cash payments, which help generate steady income streams, characteristic of preferred stocks.

What types of properties does Presidio invest in?

Presidio invests in model home properties and various commercial properties, including industrial and retail spaces.

Who can I contact for more information regarding investments?

Investors can contact Lowell Hartkorn at Presidio Property Trust through the provided contact details for any inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

PotlatchDeltic Reveals Tax Implications for 2024 Shareholder Dividends

Updated Category News Views 247

PotlatchDeltic Reveals Dividend Tax Treatment for 2024 PotlatchDeltic Corporation (Nasdaq: PCH) is stepping into the spotlight by announcing the tax treatment for its anticipated dividend distributions throughout the year. As a prominent player in the real estate investment sector, this announcement brings clarity to investors regarding how dividends will be categorized...

Continue Reading
Beyond Air Secures $3.25 Million from Warrant Exercises

Updated Category News Views 158

Beyond Air's Strategic Moves to Boost Capital Beyond Air, Inc. (NASDAQ: XAIR), a leading medical device and biopharmaceutical company, is making waves in the financial realm. Focused on the innovative use of nitric oxide (NO) to enhance patient care, Beyond Air has announced the immediate exercise of certain outstanding warrants, aiming to generate approximately $3.25...

Continue Reading
Dr. Sven Kili Joins Saisei Ventures as New Partner

Updated Category News Views 194

Saisei Ventures Welcomes Dr. Sven Kili as Partner Saisei Ventures, a prominent investment firm focused on the advancement of biotechnology and therapeutic innovations, has announced an exciting new chapter in its journey. Dr. Sven Kili, MD, has been appointed as a partner, marking a significant addition to the team's leadership. Dr. Kili, who played an advisory role since...

Continue Reading
MangoRx Unveils Innovative Tirzepatide Tablet for Weight Loss

Updated Category News Views 192

Mangoceuticals, Inc. (NASDAQ: MGRX) launched its new oral Tirzepatide tablet, TRIM, back in 2024 at a steep price of $399 per month. Traders noticed this shift towards a convenient alternative to traditional injectables and were already debating the long-term implications on sales and market share. TRIM's Role: A Game Changer for Weight Management? Tirzepatide has made...

Continue Reading
Mama’s Creations Q2 FY2025 Earnings Call Announcement

Updated Category News Views 77

Mama’s Creations to Host Earnings Call for Second Quarter FY2025 Mama’s Creations, Inc. (NASDAQ: MAMA), a leading national marketer and manufacturer of fresh deli prepared foods, is preparing to announce its financial results for the fiscal second quarter, which ended on July 31. The earnings call is scheduled to take place after the market closes on September 10....

Continue Reading